In the United States alone, drug-resistant bacteria and fungi infect almost 3 million people per year and kill about 35,000. Antibiotics are essential and effective, but in recent years overuse has led to some bacteria developing resistance to them. The infections are so difficult to treat, the World Health Organization deemed antibiotic resistance a top 10 global public health threat. Now, Professor John E. Moses at Cold Spring Harbor Laboratory (CSHL) has created a new weapon against these drug-resistant superbugs—an antibiotic that can shape-shift by rearranging its atoms. Moses came up with the idea of shape-shifting antibiotics while observing tanks in military training exercises. With rotating turrets and nimble movements, the tanks could respond quickly to possible threats.

A few years later, Moses learned of a molecule called bullvalene. Bullvalene is a fluxional molecule, meaning its atoms can swap positions. This gives it a changing shape with over a million possible configurations—exactly the fluidity Moses was looking for. Several bacteria, including MRSA, VRSA, and VRE, have developed resistance to a potent antibiotic called vancomycin, used to treat everything from skin infections to meningitis. Moses thought he could improve the drug’s bacteria-fighting performance by combining it with bullvalene. He turned to click chemistry, a Nobel Prize–winning class of fast, high-yielding chemical reactions that “click” molecules together reliably. This makes the reactions more efficient for wide-scale use.

“Click chemistry is great,” says Moses, who studied this revolutionary development under two-time Nobel laureate K. Barry Sharpless. “It gives you certainty and the best chance you’ve got of making complex things.”

Using this technique, Moses and his colleagues created a new antibiotic with two vancomycin “warheads” and a fluctuating bullvalene center. Moses tested the new drug in collaboration with Dr. Tatiana Soares da-Costa (University of Adelaide). The researchers gave the drug to VRE-infected wax moth larvae, which are commonly used to test antibiotics. They found the shape-shifting antibiotic significantly more effective than vancomycin at clearing the deadly infection. Additionally, the bacteria didn’t develop resistance to the new antibiotic.

Researchers can use click chemistry with shape-shifting antibiotics to create a multitude of new drugs, Moses explains. Such weapons against infection may even be key to our species’ survival and evolution. “If we can invent molecules that mean the difference between life and death,” he says, “that’d be the greatest achievement ever.”

Source: https://www.cshl.edu/

CF-301 is a bacteriophage-derived lysin with potent activity against Staphylococcus aureus (“Staph aureus”) bloodstream infections. CF-301 is the first and only lysin to enter human clinical trials in the US and has recently completed a Phase 1 trial in healthy volunteers. This compound is being developed for the treatment of Staph aureus bloodstream infections (BSI; bacteremia), including endocarditis, caused by methicillin-resistant and susceptible Staphaureus (MRSA and MSSA) strains.

CLICK ON THE IMAGE TO ENJOY THE VIDEO

New drug-resistant strains of Staph aureus have been identified which demonstrate resistance against vancomycin and daptomycin, the only two standard-of-care (SOC) antibiotics indicated for the treatment of MRSA BSI in the US. CF-301 has the potential to be a first-in-class, new treatment for Staph aureus bacteremia. CF-301 has specific and rapid bactericidal activity against Staph aureus. Combinations of CF-301 with vancomycin or daptomycin increased survival significantly in animal models of disease when compared to treatment with SOC antibiotics or CF-301 alone. CF-301 targets a highly conserved region of the cell wall that is vital to bacteria, thus making resistance less likely to develop. When used in combination with SOC antibiotics, the result is a novel combination therapy that has the potential to combat the high unmet clinical need of Staph aureus infections.

Advantages are important:

• Combination with antibiotics offers a superior treatment approach based on animal models
• Act at least 12x faster than current antibiotics
• Specifically kills Staph aureus and spares good bacteria
• Clears biofilm

Source: https://www.contrafect.com/